LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Trial Profile

LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 11 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 16 Feb 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top